Unlocking The Potential of Neuropeptide Y6 for Psychiatric Disorders

Unlocking The Potential of Neuropeptide Y6 for Psychiatric Disorders

Neuropeptide Y6 (NPY6) is a neurotransmitter that plays a crucial role in the regulation of various physiological processes in the brain, including motivation, pleasure, and reward.NPY6 is a potent modulator of dopamine release and has been implicated in a wide range of neuropsychiatric and neurological disorders.Despite its importance, the molecular mechanisms underlying NPY6 function remain poorly understood.

The NPY6 receptor is a G protein-coupled receptor that is expressed in many different tissues and cells throughout the body. It is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The transmembrane domain of NPY6 contains a well- conserved region known as the catalytic site, which is responsible for the binding of neurotransmitters.

The catalytic site of the NPY6 receptor is composed of a unique arrangement of amino acids that are highly conserved across species. This conserved order is important for the stability and functional relevance of the catalytic site, and suggests that it plays a central role in the NPY6 receptor.

Several studies have identified key mutations in the catalytic site of the NPY6 receptor that are associated with decreased function. These mutations have been implicated in a range of neuropsychiatric and neurological disorders, including depression, anxiety, and addiction.

In addition to its role in neurotransmission, the NPY6 receptor is also a potential drug target. The high degree of conservation in the catalytic site makes it an attractive target for small molecules that can modulate the activity of the receptor. Several compounds have been shown to interact with the NPY6 receptor and enhance its function, including the neurotransmitter itself.

One of the most promising compounds is a peptide called Y623, which is derived from the amino acids that are conserved in the catalytic site of the NPY6 receptor. Y623 has been shown to enhance the release of dopamine from the NPY6 receptor, which is a key component of the neurotransmission that is affected in various psychiatric and neurological disorders.

In addition to its potential as a drug, Y623 is also being investigated as a biomarker for the diagnosis and monitoring of neuropsychiatric disorders. The ability to generate a specific peptide that interacts with the NPY6 receptor and enhances its function makes it an attractive tool for the study of this receptor and its role in the development of various psychiatric and neurological disorders.

In conclusion, the NPY6 receptor is an important target for the development of new drugs and biomarkers for the treatment of psychiatric and neurological disorders. The conservation of the catalytic site of the NPY6 receptor makes it a promising target for small molecules, and the high degree of expression of the receptor across different tissues and cells makes it an attractive target for diagnostic studies. Further research is needed to fully understand the molecular mechanisms underlying the NPY6 receptor and its role in the regulation of neurotransmission.

Protein Name: Neuropeptide Y Receptor Y6 (pseudogene)

Functions: When expressed, is unable to bind pancreatic polypeptide (PP), neuropeptide Y (NPY), or peptide YY (PYY), suggesting that either it is functionally inactive or that it may have acquired a pancreatic polypeptide-independent function

The "NPY6R Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPY6R comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS | NRSN1 | NRSN2 | NRSN2-AS1 | NRTN | NRXN1 | NRXN2 | NRXN2-AS1 | NRXN3 | NSA2 | NSA2P2 | NSD1 | NSD2 | NSD3 | NSDHL | NSF | NSFL1C | NSFP1 | NSG1 | NSG2 | NSL complex | NSL1 | NSMAF | NSMCE1 | NSMCE1-DT | NSMCE2 | NSMCE3 | NSMCE4A | NSMF | NSRP1 | NSUN2 | NSUN3 | NSUN4 | NSUN5 | NSUN5P1 | NSUN5P2 | NSUN6 | NSUN7